Brian Thomas Biography and Net Worth

Founder & Former CEO of Metagenomi

Dr. Brian C. Thomas is Founder and former CEO of Metagenomi, Inc. He currently serves as chairperson of the board of directors of Haya Therapeutics. Dr. Thomas spent over two decades in academic research at UC Berkeley, pioneering in the field of metagenomics. He has been cited over 18,000 times, as well as being listed as an inventor on numerous patents.

Dr. Thomas started Metagenomi after seeing the need for disruption in the gene editing space and the potential of metagenomics to solve critical problems facing mankind. By mining genomes recovered from unknown life forms found in natural environments, he realized the potential of developing new gene editing technologies that could be useful for treating genetic disease.

Dr. Thomas holds both a BS in Cellular and Molecular Biology and a PhD in Biochemistry from The University of Kansas, and his postdoctoral research was completed at UC Berkeley.

What is Brian C. Thomas' net worth?: The estimated net worth of Brian C. Thomas is at least $2.90 million as of December 5th, 2025. Dr. Thomas owns 2,510,960 shares of Metagenomi stock worth more than $2,900,159 as of September 25th. This net worth evaluation does not reflect any other investments that Dr. Thomas may own. Learn More about Brian C. Thomas' net worth.
How do I contact Brian C. Thomas?: The corporate mailing address for Dr. Thomas and other Metagenomi executives is 5959 Horton Street, 7th Floor, Emeryville, CA, 94608. Metagenomi can also be reached via phone at 510-871-4880 and via email at [email protected]. Learn More on Brian C. Thomas' contact information.
Has Brian C. Thomas been buying or selling shares of Metagenomi?: Brian C. Thomas has not been actively trading shares of Metagenomi within the last three months. Most recently, Brian C. Thomas sold 3,830 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $1.77, for a transaction totalling $6,779.10. Following the completion of the sale, the director now directly owns 2,510,960 shares of the company's stock, valued at $4,444,399.20. Learn More on Brian C. Thomas' trading history.
Are insiders buying or selling shares of Metagenomi?: During the last year, Metagenomi insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $23,400.00. During the last year, insiders at the sold shares 4 times. They sold a total of 9,871 shares worth more than $15,847.42. The most recent insider tranaction occured on September, 9th when Director Laurence Reid bought 20,000 shares worth more than $23,400.00. Insiders at Metagenomi own 12.5% of the company. Learn More about insider trades at Metagenomi.
Information on this page was last updated on 9/9/2026.

Brian C. Thomas Insider Trading History at Metagenomi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2025	Sell	3,830	$1.77	$6,779.10	2,510,960
9/5/2025	Sell	2,701	$1.81	$4,888.81	2,514,790
6/6/2025	Sell	10,785	$1.75	$18,873.75	2,517,491

Brian C. Thomas Buying and Selling Activity at Metagenomi

Metagenomi Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Today's Range

Now: $1.16

$1.14

$1.17

50 Day Range

MA: $1.19

$1.10

$1.24

2 Week Range

Now: $1.16

$1.07

$3.95

Volume

28,331 shs

Average Volume

197,424 shs

Market Capitalization

$43.64 million

P/E Ratio

N/A

Dividend Yield